On May 16, Johnson & Johnson announced that it had reached an agreement withProteologix Reaches Final Agreement to Acquire for $850 Million in CashProteologix, besides,Proteologix is also eligible for additional milestone payments.
Proteologix focuses on developing bispecific antibodies for the treatment of immune-mediated diseases. Its product portfolio includes: 1) PX128, a bispecific antibody targeting IL-13 and TSLP, which is about to enter Phase I clinical trials for the treatment of moderate to severe atopic dermatitis (AD) and moderate to severe asthma; 2) PX130, a bispecific antibody targeting IL-13 and IL-22, intended for development in moderate to severe AD, currently in the preclinical development stage.Due to AD and asthmaAll are heterogeneous diseases,Different Patient SubgroupsThere are differentPathogenic Pathway，ThereforeMulti-Pathway TargetingExpected to achieveBetter efficacy and remission rates.Currently, Johnson & JohnsonAroundSolid Tumors, Hematological TumorsTumor andMultiple bispecific antibody products have been developed for autoimmune diseases.Among them, for non-small cell lung cancerEGFR/c-MET Bispecific Antibody AmivantamabAnti-, treating multiple myelomaGPRC5D/CD3Taqiutumab andBCMA/CD3 Bispecific AntibodyTalimogene laherparepvec has already been approved by the FDA for marketing. Additionally, 18 products are in Phase I~II clinical stages, and there are 10 products in the preclinical stage.The press release introduced that, this acquisitionThese twoPaymentProductAll for the purpose ofReduceDesigned to reduce the frequency of administration，For patientsProvided convenience, with hopes of collaborating with Johnson & JohnsonExisting bispecific antibody pipelineComplementary to each other.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.↑Long press to scan the QR code, fill in the form to register↑
